Showing 4651-4660 of 10637 results for "".
Primary Results of the VESALIUS-CV Trial: Evolocumab in Patients at High Cardiovascular Risk Without Prior MI or Stroke
https://reachmd.com/clinical-practice/cardiology/primary-results-of-the-vesalius-cv-trial-evolocumab-in-patients-at-high-cardiovascular-risk-without-prior-mi-or-stroke/45568/Dr. Erin Bohula reviews VESALIUS-CV trial findings on evolocumab for primary Cardiovascular prevention in patients at high CV risk without prior MI or stroke.Rising Stimulant Use Among Patients with HIV: What 5 Years of Clinic Data Reveal
https://reachmd.com/programs/clinicians-roundtable/rising-stimulant-use-among-patients-with-hiv-what-5-years-of-clinic-data-reveal/32827/At Alabama’s only integrated infectious diseases and substance use clinic, clinicians are seeing a sharp rise in stimulant use among patients with opioid use disorder and HIV. That’s why they conducted a five-year retrospective study analyzing how comorbid stimulant use impacts clinical outcomes. WhHow GLP-1s Provide New Options to Manage Heart Disease
https://reachmd.com/programs/medical-industry-feature/how-glp-1s-provide-new-options-to-manage-heart-disease/29921/Hear more about how GLP-1s are going beyond weight loss to address heart disease, revealing new ways in which these therapies can help manage complex cardiac conditions.Navigating Treatment Goals in IgAN: The Impact of ET-1 and Ang II
https://reachmd.com/programs/clinicians-roundtable/navigating-treatment-goals-in-igan-the-impact-of-et-1-and-ang-ii/37214/Given that the endothelin-1 (ET-1) and angiotensin II (Ang II) pathways contribute to the pathogenesis of IgA nephropathy (IgAN), it’s important to set treatment goals that prevent disease progression. Joining Dr. Charles Turck to discuss the role and impacts of ET-1 and Ang II and how we can achievReal-World Data Highlights Class-Based Differences in Psoriasis Biologic Outcomes
https://reachmd.com/programs/dermconsult/real-world-data-highlights-class-based-differences-in-psoriasis-biologic-outcomes/36369/CAR T in Marginal Zone Lymphoma: Insights from the TRANSCEND FL Study
https://reachmd.com/programs/project-oncology/car-t-in-marginal-zone-lymphoma-insights-from-the-transcend-fl-study/35455/This is a non-certified educational series produced and controlled by ReachMD. CAR T-cell therapies have helped transform the treatment of aggressive lymphomas, but could they also change the game for slower-growing, harder-to-treat diseases like marginal zone lymphoma? Based on new data from the TRIntermittent Calorie Restriction Alters Immune and Metabolic Markers in RRMS
https://reachmd.com/programs/neurofrontiers/Intermittent-Calorie-Restriction-Alters-Immune-and-Metabolic-Markers-in-Relapsing-Remitting-Multiple-Sclerosis/36352/Exploring Timing in MS Therapy: Real-World Outcomes of Fumarates
https://reachmd.com/programs/neurofrontiers/exploring-timing-in-ms-therapy-real-world-outcomes-of-fumarates/32805/Treating Primary Biliary Cholangitis with Seladelpar: Insights from the RESPONSE Trial
https://reachmd.com/programs/gi-insights/treating-primary-biliary-cholangitis-with-seladelpar-insights-from-the-response-trial/29162/Based on the RESPONSE trial, seladelpar may be a safe and effective treatment for primary biliary cholangitis patients who don’t response to current therapies.How Air Pollution Affects the Skin
https://reachmd.com/programs/practical-dermatology/how-air-pollution-affects-the-skin/24041/An Interview with Dr. Mark Birch-Machin